Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on August 28, 2023. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Note: While the request metadata references "Envue Medical, Inc.", the filing text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on a regulatory disclosure event rather than financial performance results.
Material Changes
The primary material event reported is the Company's application for the inclusion of its UroShield products in the National Health Service (NHS) Prescription Services' Drug Tariff. This development was announced via a press release dated August 28, 2023, which is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release regarding the NHS Drug Tariff application but provided no specific financial guidance or forward-looking projections in this filing.
- Contingencies and Risks: The filing includes a standard disclaimer stating the Company undertakes no obligation to update, supplement, or amend the materials attached. The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the status of the UroShield product application with the NHS Prescription Services.
- Review the full text of the press release (Exhibit 99.1) for details on the potential commercial impact of NHS inclusion.
- Confirm the distinction between the registrant (NanoVibronix, Inc.) and any other entities mentioned in external metadata.
- Monitor future filings for updates on the Drug Tariff decision, as the Company has not committed to providing updates in this document.